<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05125991</url>
  </required_header>
  <id_info>
    <org_study_id>IEO 1002/</org_study_id>
    <nct_id>NCT05125991</nct_id>
  </id_info>
  <brief_title>Evaluation of the Effectiveness of Prepectoral Breast Reconstruction</brief_title>
  <official_title>Evaluation of the Effectiveness of the Prepectoral Breast Reconstruction With Braxon Dermal Matrix: a Randomized Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Institute of Oncology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European Institute of Oncology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study plans to compare conventional submuscular reconstruction with definitive implant&#xD;
      and muscle sparing reconstruction with definitive implant in selected patients. The two&#xD;
      techniques are compared in terms of patient quality of life and satisfaction; patient related&#xD;
      outcomes, reconstruction morbidity, early and late complications are also investigated.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study plans to compare conventional submuscular reconstruction with definitive implant&#xD;
      and muscle sparing reconstruction with definitive implant in selected patients. The two&#xD;
      techniques are compared in terms of patient quality of life and satisfaction; patient related&#xD;
      outcomes, reconstruction morbidity, early and late complications are also investigated.&#xD;
&#xD;
      The study plans to collect robust data to support the prepectoral implant placement and&#xD;
      complete coverage of implant with acellular dermal matrix in the clinical practice.&#xD;
&#xD;
      Consequently, the project plans to move toward evidence-based medicine in breast&#xD;
      reconstruction, avoiding marketing influences and surgeon experience as the sole source of&#xD;
      evidence.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 3, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Satisfaction assessed by the BREAST-Q</measure>
    <time_frame>1 year</time_frame>
    <description>The BREAST-Q survey is used to detect differences in patient satisfaction among the groups</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immediate complications rate</measure>
    <time_frame>1 month</time_frame>
    <description>Compare post operative complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short term complications rate</measure>
    <time_frame>6 months</time_frame>
    <description>Compare short term post operative complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long term complications rate</measure>
    <time_frame>24 months</time_frame>
    <description>Compare long term post operative complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of capsular contracture</measure>
    <time_frame>1 year</time_frame>
    <description>Compare overall aesthetic outcomes (percentage of capsular contracture) using standardized photographs assessed by independent blinded observers</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">58</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Prepectoral reconstruction</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prepectoral breast reconstruction with Braxon dermal matrix</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Submuscular reconstruction</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Submuscolar breast reconstruction</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Prepectoral reconstruction</intervention_name>
    <description>Prepectoral breast reconstruction</description>
    <arm_group_label>Prepectoral reconstruction</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Submuscolar reconstruction</intervention_name>
    <description>Submuscolar breast reconstruction</description>
    <arm_group_label>Submuscular reconstruction</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Informed consent&#xD;
&#xD;
          2. Not smokers&#xD;
&#xD;
          3. No vascular comorbidities (diabetic, vasculitis, coagulation disorders)&#xD;
&#xD;
          4. BMI&lt;30&#xD;
&#xD;
          5. CUP B-C (or mastectomy estimated weight less than 550gm)&#xD;
&#xD;
          6. Good subcutaneous layer (&gt;1cm on pinch test measured in upper/medial quadrant)&#xD;
&#xD;
          7. No previous breast surgery&#xD;
&#xD;
          8. No previous breast irradiation&#xD;
&#xD;
          9. Breast Ptosis 1-2 according to Renault's classification&#xD;
&#xD;
         10. DCIS tumors&#xD;
&#xD;
         11. T1 T2 pN0 breast tumor with known favourable biologic features&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Impossibility of immediate reconstruction with definitive implants due to inadequacy&#xD;
             of mastectomy flaps (inadequate in quantity and/or quality)&#xD;
&#xD;
          2. Positive sentinel node biopsy requiring complete axillary dissection&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francesca De Lorenzi, PhD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>European Institute of Oncology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Paolo Veronesi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>European Institute of Oncology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Francesca De Lorenzi, PhD, MD</last_name>
    <phone>+390257489394</phone>
    <email>francesca.delorenzi@ieo.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pietro Sala, MD</last_name>
    <phone>+390257489394</phone>
    <email>pietro.sala@ieo.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>European Institute of Oncology</name>
      <address>
        <city>Milan</city>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesca De Lorenzi, MD</last_name>
      <phone>+390257489394</phone>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 25, 2021</study_first_submitted>
  <study_first_submitted_qc>November 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 18, 2021</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

